Hematopoietic stem cells (HSCs) are important in cell-based therapies for blood-related disorders. While progress has been made in generating HSCs by directed differentiation of pluripotent stem cells (PSCs), such cultures promote hematopoietic progenitor cells (HPCs) over HSCs. Thus, elucidating markers and factors associated with HSC versus HPC development is imperative. HSCs and HPCs originate from hemogenic endothelium (HE) in a Runx1-dependent process. Here, we characterize a Runx1 enhancer (+110) that distinguishes emerging dorsal aorta HSCs from HPCs. Comparative transcriptomics reveal a 17-gene signature associated with in vivo long-term HSC potential, while single-cell multiome analysis demonstrates a clear epigenetic identity of dorsal aorta HE, preHSCs, and HPCs, providing a resource of stage-specific enhancer activity. Our study demonstrates the power of cell type-specific enhancer-reporter models to dissect cell fate decisions in development and provides new inroads to label and/or perturb HSC versus HPC potential in vivo and in vitro.

Anselmi, G., Frontera, V., Rode, C., Jarratt, A., Mehmood, N., Nicholls, M., et al. (2026). Resolving hematopoietic stem versus progenitor cell potential in the mouse dorsal aorta by differential Runx1 +110 enhancer activity. CELL REPORTS, 45(8), 1-18 [10.1016/j.celrep.2026.117737].

Resolving hematopoietic stem versus progenitor cell potential in the mouse dorsal aorta by differential Runx1 +110 enhancer activity

Azzoni, Emanuele;
2026

Abstract

Hematopoietic stem cells (HSCs) are important in cell-based therapies for blood-related disorders. While progress has been made in generating HSCs by directed differentiation of pluripotent stem cells (PSCs), such cultures promote hematopoietic progenitor cells (HPCs) over HSCs. Thus, elucidating markers and factors associated with HSC versus HPC development is imperative. HSCs and HPCs originate from hemogenic endothelium (HE) in a Runx1-dependent process. Here, we characterize a Runx1 enhancer (+110) that distinguishes emerging dorsal aorta HSCs from HPCs. Comparative transcriptomics reveal a 17-gene signature associated with in vivo long-term HSC potential, while single-cell multiome analysis demonstrates a clear epigenetic identity of dorsal aorta HE, preHSCs, and HPCs, providing a resource of stage-specific enhancer activity. Our study demonstrates the power of cell type-specific enhancer-reporter models to dissect cell fate decisions in development and provides new inroads to label and/or perturb HSC versus HPC potential in vivo and in vitro.
Articolo in rivista - Articolo scientifico
embryo; endothelial-to-hematopoietic transition; enhancers; hematopoietic stem cells; HSC specification; intra-aortic clusters; lineage potential; Runx1;
English
30-lug-2026
2026
45
8
1
18
117737
open
Anselmi, G., Frontera, V., Rode, C., Jarratt, A., Mehmood, N., Nicholls, M., et al. (2026). Resolving hematopoietic stem versus progenitor cell potential in the mouse dorsal aorta by differential Runx1 +110 enhancer activity. CELL REPORTS, 45(8), 1-18 [10.1016/j.celrep.2026.117737].
File in questo prodotto:
File Dimensione Formato  
Anselmi et al-2026-Cell Reports-VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 6.33 MB
Formato Adobe PDF
6.33 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/621485
Citazioni
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
Social impact